Morgan Stanley Midatech Pharma PLC Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$0.46 - $1.0 $46,410 - $100,893	-100,893 Reduced 55.03%	82,444 $45,000
Q2 2022 Aug 15, 2022	SELL	$0.46 - $1.0 $46,410 - $100,893	-100,893 Reduced 55.03%	82,444 $45,000
Q1 2022 Oct 27, 2022	BUY	$0.83 - $1.26 $83,741 - $127,125	100,893 Added 122.38%	183,337 $161,000
Q1 2022 May 13, 2022	BUY	$0.83 - $1.26 $30,037 - $45,599	36,190 Added 24.59%	183,337 $161,000
Q4 2021 Feb 14, 2022	SELL	$1.05 - $1.85 $14,327 - $25,243	-13,645 Reduced 8.49%	147,147 $155,000
Q3 2021 Nov 15, 2021	BUY	$1.68 - $2.19 $270,130 - $352,134	160,792 New	160,792 $280,000

Ticker MTP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 3,939,740
Market Cap $512K
Description
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.